Acompanhe as Notícias da Recifes

A drug from the same family licensed for use in patients with Duchenne muscular dystrophy and blood cancer could transform the treatment of meningioma—the most common form of primary brain tumor in adults. Scientists at the Brain Tumor Research Center of Excellence at the Univers

At Binghamton University, researchers were among the first to find ways to help patients with Duchenne muscular dystrophy (DMD) through the development of an effective drug. Now, they are continuing that work, looking to reduce its effects even earlier.

For decades, researchers studying myotonic dystrophy type 1 (DM1) have focused on the disease's underlying genetic cause: a mutation that produces a toxic form of RNA, disrupting the normal processing of thousands of genetic messages inside cells. While scientists have known this